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Emerging multidrug-resistant bacteria are a challenge for modern medicine, but how these
pathogens are so successful is not fully understood. Robust antibacterial vaccines have
prevented and reduced resistance suggesting a pivotal role for immunity in deterring anti-
biotic resistance. Here, we show the increased prevalence of Klebsiella pneumoniae lipopo-
lysaccharide O2 serotype strains in all major drug resistance groups correlating with a paucity
of anti-O2 antibodies in human B cell repertoires. We identify human monoclonal antibodies
to O-antigens that are highly protective in mouse models of infection, even against heavily
encapsulated strains. These antibodies, including a rare anti-O2 speciﬁc antibody, syner-
gistically protect against drug-resistant strains in adjunctive therapy with meropenem, a
standard-of-care antibiotic, conﬁrming the importance of immune assistance in antibiotic
therapy. These ﬁndings support an antibody-based immunotherapeutic strategy even for
highly resistant K. pneumoniae infections, and underscore the effect humoral immunity has on
evolving drug resistance.
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Among the most problematic multidrug-resistant (MDR)bacterial pathogens are the Gram-negative carbapenem-resistant enteric bacteria (CRE), including Klebsiella
pneumoniae1, 2. K. pneumoniae colonizes the lower gastro-
intestinal tract, from which it can disseminate, particularly when
the commensal microbiota is disrupted by antibiotic treatment or
when a patient is immunocompromised3. More than a third of K.
pneumoniae clinical isolates express extended spectrum beta-
lactamases (ESBL) and are resistant to third generation cepha-
losporins, aminoglycosides, tetracycline, and other antibiotics4.
CRE isolates are additionally resistant to carbapenems and are
strongly correlated with poor patient outcome5, 6, with mortality
rates as high as 60%.
While the majority of effort on understanding the spread of
antibiotic resistance has focused on the acquisition of mutations
or resistance genes that directly affect drug susceptibility, the
most successful resistant strains clearly have additional adapta-
tions. For example, the successful spread of the CRE sequence
type 258 (ST258) clonal group is the subject of intense study
because the diverse resistance genes this group carries are not
unique to this lineage7, 8. In addition to bacterial factors, there is
growing evidence demonstrating a link between host immunity
and reduced antibiotic resistance. Since the onset of routine
vaccinations against Haemophilus inﬂuenzae, Streptococcus
pneumoniae, and Neisseria meningitidis, resistance within these
organisms has been reduced or nearly eradicated9. Effective
immunity can decrease the severity and/or duration of an infec-
tion thus lessening the need for antibiotic intervention and
reducing the selective pressure imparted by antibiotic exposure.
Host humoral immunity can also work in concert with antibiotic
therapy to synergistically clear drug-resistant pathogens that
cannot be cleared with antibiotic alone10, 11.
Lipopolysaccharide (LPS) is a critical component of the Gram-
negative bacterial outer membrane. The earliest antibody-based
strategies against Gram-negative pathogens targeted the con-
served Lipid A component of the LPS inner core with the aim of
neutralizing lipid A proinﬂammatory properties, but these efforts
failed for a variety of reasons12–15. Beyond the conserved inner
core, there are at least seven distinct Klebsiella LPS serotypes
deﬁned by unique O-antigen structures16. K. pneumoniae O1 and
O2 LPS O-antigens share the D-galactan I disaccharide unit, but
O1 also includes the D-galactan II disaccharide and is therefore
more complex in structure and larger in size17, 18. In previous
target agnostic efforts to identify antibodies against K. pneumo-
niae19, we found that LPS serotype-speciﬁc antibodies were the
most potent in promoting bacterial killing in vitro.
In this study, we survey a large collection of clinical isolates
to determine the relative prevalence of LPS serotypes, particu-
larly in multidrug-resistant isolates. We ﬁnd that LPS O2
antigen serotype has increased two to threefold in prevalence in
both K. pneumoniae ESBL and CRE multidrug-resistant strain
groups relative to the susceptible group. This ﬁnding is sur-
prising as strains expressing the O2-antigen, including
ST258 strains, are more sensitive to human serum killing than
the related O1 antigen expressing strains. We demonstrate
ST258 strains are almost exclusively the O2 serotype, but the
overall increased O2 prevalence is not limited to ST258. These
data suggest a selective advantage for the LPS O2-antigen type
in the context of antibiotic pressure. We ﬁnd that O2 strain
prevalence may be explained by its reduced immunogenicity
that imparts a stealth advantage against antibody-driven
mechanisms of clearance. In addition, we identify serotype-
speciﬁc anti-O1 and anti-O2 human monoclonal antibodies
(mAbs) that exhibit potent opsonophagocytic killing of K.
pneumoniae strains and provide protection in mouse models of
infection. These data indicate that protective non-capsular
mAbs targeting less diverse anti-O antigen types expressed by
MDR strains can be identiﬁed. Importantly, these serotype-
speciﬁc O1 and O2 antibodies synergistically augment anti-
biotic therapy even against drug-resistant strains, further sup-
porting an important role for antibody-mediated immunity in
the context of antibiotic therapy. Together, these ﬁndings
support that O-antigen immunogenic stealth provides a selec-
tive advantage to drive multidrug resistance and that protective
antibodies can synergize with antibiotic therapy, thus under-
scoring the importance of humoral immunity to drug-resistant
bacteria.
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Fig. 1 Klebsiella pneumoniae serotype O2 prevalence in MDR strains. a LPS
serotype-speciﬁc antibodies were used to determine the serotype of 709 K.
pneumoniae clinical isolates from 38 different countries by western blot. Pie
charts represent the distribution of each serotype as a percentage of the
total in each antibiotic resistant group. Susceptible, ESBL and CRE strains
are categorized based on their MIC proﬁle as described in Methods. More
information about the source of the isolates is listed in Supplementary
Table 1. b Serum sensitivity assays were performed in 45% pooled human
sera using a panel of 12 O1 isolates, 12 O2 isolates and two separate
isogenic pairs genetically converting an O2 strain to O1 (Kp961842,
magenta diamonds) or an O1 strain to O2 (Kp1131115, blue diamonds).
Percent viability is the ratio between CFUs present in buffer control media
and CFUs present in human sera after 2 h growth. c A subset of serotype
O2 isolates was further analyzed by Sanger or next generation sequencing
to determine ST types. The CRE ST258 sequence type is represented by the
shaded orange portion of each bar to highlight the percent of ST258
isolates observed in each category
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Results
O2 LPS serotype prevalence in multidrug-resistant strains. We
surveyed O-antigen serotype prevalence in a geographically
diverse strain collection consisting of 709 clinical isolates col-
lected between 2012 and 2014, from 162 different hospitals in 38
countries, spanning six continents and from a variety of body
infection sites (Fig. 1a, Supplementary Table 1). Isolates were
intentionally selected to represent comparable numbers of MDR
(both ESBL and CRE) and fully susceptible isolates to generate
the ﬁrst large-scale analysis comparing serotype distribution as a
function of antibiotic resistance. The serotype distribution
observed among antibiotic susceptible strains was largely in line
with serotype frequencies previously determined in the 1990s,
including the predominance of the O1 serotype20, 21. However,
with the development of ESBL and later emergence of CRE
strains in the last two decades, O2 serotype appears to be the
dominant serotype within both of these distinct MDR bacterial
populations in comparison to the susceptible strain population
(Fig. 1a). This result is unexpected in light of previous ﬁndings
that O1 strains are much more resistant to complement depen-
dent killing than other O serotypes22–25. Therefore, we evaluated
the relative serum susceptibility of randomly selected O1 and
O2 strains from the above clinical isolate collection to determine
if O2 strains were resistant to human serum. However, we found
O2 strains were much more sensitive to human serum killing
than strains expressing the related O1 serotype (>2000 times
more sensitive on average, Fig. 1b). Furthermore, isogenic con-
version of an O1 strain (Kp1131115) to O2 by deletion of the
wbbYZ locus resulted in a dramatic 21-fold decrease in serum
resistance, and reciprocal conversion of an O2 strain (Kp961842)
to O1 by the addition of these genes resulted in a 90-fold increase
in serum resistance (Fig. 1b).
One explanation for the dominance of the O2 serotype within
the MDR population could be an association with clonal
outbreaks, such as the pervasive CRE Klebsiella global “super
clone” ST25831–33. While we found the vast majority (85%) of
ST258 isolates to be of the O2 serotype, only 49% of the CRE O2
isolates and just 5% of ESBL O2 isolates typed as ST258 (Fig. 1c).
Therefore, simple clonal expansion does not wholly explain the
O2 prevalence in MDR strains, particularly within the ESBL
subset. While Klebsiella carbapenem resistance is most often
attributed to the acquisition of plasmid encoded kpc genes, other
genes such as oxa and the emerging ndm34, 35 are also of concern.
Interestingly, O2 was also the predominant serotype in isolates
that carry any of these genes (Supplementary Fig. 1b). These data
suggest therapeutics targeted against O2 LPS could provide better
coverage against MDR isolates than those speciﬁcally targeting
only a major sequence type such as ST258.
Klebsiella O2 LPS is less immunogenic than O1 LPS. O2 MDR
prevalence suggests an unrecognized selective advantage for these
strains, particularly since it was conﬁrmed that O2 strains are
markedly more serum susceptible and because this increased
prevalence is not entirely attributable to the success of a particular
clone. While identifying antibodies for our serotype screen, we
observed a much lower frequency of O2 speciﬁc B cells compared
to O1 or O1/O2 cross reactive B cells, possibly due to a lower
immunogenicity of the O2-antigen. To address this, human
immune responses to O1 or O2 LPS were determined using
plasma samples from 103 healthy donors and 6 O2 KP infected
ICU patients. Titers indicated a dominant IgG response to O1
LPS compared to O2 (Fig. 2a, c, d). Of note, 5 out of 6 ICU
plasma samples had anti-O2 LPS IgG antibodies, but those titers
were paralleled by high titers of anti-O1 antibodies suggesting a
signiﬁcant fraction cross-react with O1 LPS (Fig. 2a). We also
performed a clonal analysis using in vitro polyclonal stimulation,
which selectively activates memory B cells in unfractionated
tonsillar lymphocytes (antigen-speciﬁc memory B cell repertoire
analysis, AMBRA36), (Fig. 2b–d, Supplementary Fig. 2). The
frequency of LPS reactive memory B cells was higher in the IgM
repertoire as compared to the IgG repertoire (Fig. 2c, d), con-
sistent with the concept that the IgM B cell memory repertoire is
dominated by anti-polysaccharide antibodies. Interestingly, the
frequency of O2-speciﬁc memory B cells, both IgM and IgG, was
signiﬁcantly lower as compared to O1 speciﬁc. Together, these
results suggest that O2 speciﬁc antibody responses may be
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Fig. 2 Analysis of the human antibody response to K. pneumoniae O1 and O2 LPS. a O1 and O2-speciﬁc IgG antibodies were measured by ELISA in plasma
derived from 103 healthy donors (left panel) and 6 ICU patients (right panel) diagnosed with O2 K. pneumoniae infection. Shown are the endpoint titers
based on serial dilutions. Lines between data points indicate data acquired from the same sample. b–d Analysis of antigen-speciﬁc repertoires (AMBRA,
antigen-speciﬁc memory B cell repertoire analysis) from tonsillar IgG and IgM memory B cells of 33 donors (30 of the 33 were available for IgM analysis,
Supplementary Fig. 2). Total tonsillar lymphocytes were plated and stimulated with R848 and IL-2 and the 10-day culture supernatants (192 cultures per
donor) were analyzed by ELISA for the presence of IgG or IgM antibodies that bind to O1 LPS, O2 LPS or uncoated control plates. The OD values obtained
from the analysis of uncoated plates were subtracted from the analysis of the O1 and O2 speciﬁc responses. b Shown are ELISA OD values of individual
cultures from the analysis of one representative donor. Cut-off values are indicated by a dotted line. O1, O2 and O1/O2 reactive cultures are represented as
magenta, blue and orange circles, respectively. c, d Each data point represents the frequency of the cultures (n= 192) scoring as positive for IgG (c) or IgM
(d) reactivity to O1 or O2 LPS for each of the donors analyzed, according to the cut-off values shown in b. Data was analyzed using the Wilcoxon matched-
pair signed rank test to assess signiﬁcance. ****p< 0.0001
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disproportionately lower than O1 or O1/O2 cross-reactive anti-
body responses.
To further investigate the immunogenicity of O1 and O2, mice
and rabbits were immunized with puriﬁed O1 or O2 LPS. While
O1 LPS-immunized animals had high titers against O1 LPS, O2
LPS-immunized animals had very low titers against O2 LPS
(Fig. 3a, b). The poor antibody response to O2 LPS in animals is
consistent with the human data. Mice were also immunized with
either member of an isogenic O1/O2 bacteria pair. Mice
immunized with the O1-expressing wild-type (WT) strain
generated high titers of antibodies against O1 LPS, while those
immunized with the isogenic O2-expressing ΔwbbYZ strain did
not generate a detectable response towards O2 LPS (Fig. 3c).
Either immunization generated equivalent titers to outer
membrane protein A (OmpA) and to a total carbohydrate extract
(Fig. 3d). Additionally, both LPS serotypes stimulated a NF-κB-
driven luciferase reporter gene to the same degree, indicating that
O2 LPS is not defective in stimulating TLR4-driven inﬂammatory
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responses (Fig. 3e). O2 LPS is less complex in structure and has a
lower molecular weight than O1 LPS (Fig. 3f, g) which may
contribute to its reduced antigenicity, consistent with prevailing
ﬁndings that T-cell-independent type 2 antigens require larger
molecular weight, repetitive antigenic epitopes to effectively
cross-link B-cell receptors to stimulate antibody responses24, 37,
38. Together, these data illustrate the weak antigenicity of O2-
antigen and suggest that less antibody-mediated protection
against O2 strains may contribute to their higher prevalence,
particularly among recently emerging MDR strains against which
antibiotic therapy is marginal.
O1 and O2 LPS speciﬁc mAbs mediate opsonophagocytic
killing. In an effort to ﬁnd functional protective mAbs, human
peripheral blood and tonsil memory B cells were next isolated
based on reactivity against puriﬁed O1 and O2 LPS, the most
prevalent serotypes found in clinical isolates (Fig. 1a). All anti-
LPS mAbs isolated were IgG2, consistent with the concept that
this is the predominant IgG subclass produced in response to
polysaccharides, but were converted and recombinantly expressed
as human IgG1 for functional analysis. Several O1/O2 cross-
reactive antibodies were identiﬁed and exempliﬁed by mAb
KPN70 which exhibited very high binding afﬁnity to both O1
(~KD = 0.18 nM) and O2 (~KD = 0.06 nM) LPS, likely recogniz-
ing the shared O1/O2 polysaccharide component D-galactan I
(Fig. 4a). Similarly, anti-O1 mAbs with strong binding speciﬁcity
were readily identiﬁed and exempliﬁed by mAb KPE33 (~KD =
1.8 nM). Consistent with the above data, O2 speciﬁc mAbs were
exceedingly rare. Nevertheless, mAb KPN42 was isolated and
determined to be highly speciﬁc for O2 LPS (~KD = 4.3 nM).
Further binding analysis on O1 LPS showed no competition
between KPE33 and KPN70, indicating that they recognize dif-
ferent epitopes on O1 LPS (Supplementary Fig. 3). Similarly,
KPN42 did not block KPN70 binding to O2 LPS, however, the
higher afﬁnity mAb KPN70 partially blocked the binding of
KPN42. This uni-directional blocking might be due to allosteric
or steric hindrance caused by the binding of a high afﬁnity mAb
(in this case KPN70) near the binding region of a lower afﬁnity
mAb (KPN42). Overall, these binding data suggest recognition of
distinct, albeit proximal, epitopes on O2 LPS by mAbs KPN70
and KPN42, and on O1 LPS by mAbs KPN70 and KPE33.
Binding to whole bacteria was also analyzed by confocal micro-
scopy. KPE33 and KPN42 uniformly bound the bacterial surface
of encapsulated O1 and O2 strains, respectively, while the cross-
reactive mAb KPN70 displayed a similar uniform pattern on the
O2 strain, but exhibited a punctuate staining pattern on the
O1 strain (Fig. 4b). The reduced binding of KPN70 to the surface
of O1 strains compared to puriﬁed O1 LPS is likely due to limited
accessibility of this epitope in the context of O1 vs. O2 whole
bacteria. In support of this hypothesis, KPN70 bound to O2 but
not O1 strains as measured by ﬂow cytometry (Supplementary
Fig. 6a). In addition, strains that were converted from O1 to
O2 showed enhanced KPN70 binding, and strains that were
converted from O2 to O1 had reduced binding (Supplementary
Fig. 6b). O-antigen was conﬁrmed to be the target antigen of each
of the mAbs (KPE33, KPN42 and KPN70) as they do not bind to
mutant strains deﬁcient in O-antigen expression (ΔwecA
mutants, Supplementary Fig. 6c).
Additional assays were performed to assess the functional
activity of the mAbs. LPS neutralization assays demonstrated that
both O1 and O2 LPS were potent stimulators of NF-κB driven
expression of luciferase. Interestingly, only KPN70 exhibited LPS
neutralization activity (Fig. 4c), indicating that antibody binding
to O-antigen does not necessarily result in blocking LPS
activation of host target cells. Next, the mAbs were assessed for
opsonophagocytic killing activity against luminescent wild-type
and isogenic capsule-deﬁcient K. pneumoniae strains. None of the
mAbs mediated killing of wild-type encapsulated strains
(Supplementary Fig. 4). When capsule-deﬁcient mutant strains
were used, the O1-speciﬁc mAb KPE33 mediated dose-dependent
killing of the O1, but not the O2, target strain (Fig. 4d).
Conversely, the O2-speciﬁc mAb KPN42 effectively mediated
killing of the O2 strain only. Interestingly, the O1/O2 cross-
reactive mAb KPN70 mediated opsonophagocytic killing activity
only against the O2, but not the O1, target strain, possibly due to
the lack of uniform binding on the bacterial cell surface as seen by
confocal imaging (Fig. 4b).
Anti-O-antigen in vivo protection is serotype speciﬁc. Given
their opsonophagocytic killing of two prominent LPS serotypes
(summarized in Fig. 4e), we tested the protective potential of
these mAbs in murine models of K. pneumoniae infection against
wild-type encapsulated strains. Since each mAb targets a unique
LPS antigen (O1 or O2), murine models were developed inde-
pendently as a mimic of various clinical K. pneumoniae infec-
tions. The serotype-speciﬁc anti-O1 (KPE33) and anti-O2
(KPN42) mAbs signiﬁcantly improved survival outcomes com-
pared to the negative control mAb when used to treat infection
with an O1 or O2 strain, respectively, in acute murine pneumonia
(Fig. 5a) and bacteremia (Fig. 5b) models. In the bacteremia
model, mortality is more rapid with a lower bacterial challenge
dose than the pneumonia model resulting in a narrower ther-
apeutic window. As such, the mAbs were most effective when
administered prophylactically (Fig. 5b) vs. in treatment (Supple-
mentary Fig. 5b), though either mAb delivery was signiﬁcantly
protective. Despite its high afﬁnity binding to both O1 and O2
LPS and its potent LPS neutralizing activity, the anti-O1/O2
cross-reactive mAb KPN70 failed to improve survival outcome in
the murine pneumonia model with an O1 strain and only
moderately improved survival with an O2 strain (Fig. 5a).
Interestingly, KPN70 had some activity against both an O1 strain
and O2 strain in bacteremia (Fig. 5b, Supplementary Fig. 5b). The
Fig. 3 K. pneumoniae O2 LPS is less immunogenic than K. pneumoniae O1 LPS. Puriﬁed O1 and O2 LPS were used for immunization of mice (a) or rabbits (b)
with 0.5 mg LPS per animal. Immune sera were collected from O1 and O2 immunized animals and used to assess antibody titer against KP O1 or O2 LPS by
ELISA. Sera from mock immunized animals with adjuvant only (black open circle) were used as a negative control. cMice were immunized subcutaneously
with either heat killed Kp1131115 (WT, an O1 strain) or the isogenic matched Kp1131115ΔwbbYZ (ΔwbbYZ, O2 serotype). Sera were collected 7 days after
the ﬁnal injection and used to assess antibody titer against K. pneumoniae O1 or O2 LPS by ELISA. d Sera collected in c were used to assess antibody binding
to a protein target (OmpA) and to proteinase K bacterial lysate by ELISA. e Immune activation of cells in vitro was compared for puriﬁed O1 and O2 LPS.
RAW264.7 cells stably transfected with a NF-κB driven luciferase promoter were stimulated with various doses of K. pneumoniae O1 or K. pneumoniae
O2 LPS for 2 h. Percent activation was calculated as the amount of luminescence in stimulated cells vs. non-stimulated. Error bars indicate s.d. of each data
point. f A schematic representation of KP O1 and O2 LPS. The gray region represents the membrane proximal LPS core region, the black region represents
the D-galactan I (D-gal I) repeating O antigen sugars, the hatched gray ﬁlled region represents the O1 speciﬁc D-galactan II (D-gal II) repeating O antigen
sugars encoded by the wbbYZ locus. Deletion of this locus converted the O1 strain (Kp1131115 WT) to an O2 expressing strain (Kp1131115ΔwbbYZ). g Silver
stain of a SDS-PAGE gel showing the relative molecular weight of K. pneumoniae O1 LPS (lane 2) vs. K. pneumoniae O2 LPS (lane 3)
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Fig. 4 In vitro characterization of anti-O antigen mAbs. a Association/dissociation curves of K. pneumoniae O1 or K. pneumoniae O2 LPS binding to mAbs
KPE33, KPN70, and KPN42 were measured by ForteBio Octet using protein A capture probe pre-loaded with each mAb. b Confocal images of mAb binding
to an O1 (Kp43816) or O2 (Kp9148) strain (scale bar, 2 μm). c LPS neutralization was measured using RAW264.7 cells transfected with a NK-kB driven
luciferase promoter stimulated with 2 ngml−1 of puriﬁed O1 or O2 LPS in the presence of KPE33, KPN70, KPN42 or the isotype-matched control mAb (c-
IgG). Percent inhibition was calculated as the amount of luminescence (RLU) in treated wells divided by the RLU in wells stimulated with LPS alone
multiplied by 100. d Opsonophagocytic killing assays were performed using various concentrations of mAbs in the presence of the phagocytic cell line HL-
60. The capsule-deﬁcient luminescent mutants Kp43816ΔcpsB and Kp8570ΔcpsB were used as the O1 and O2 serotype targets, respectively. Percent
killing was calculated based on the amount of luminescence after 2.5 h incubation in treated wells vs. wells with bacteria only. An isotype-matched mAb (c-
IgG) is used as a negative control. e Summary of the in vitro functional activities against O1 and O2 K. pneumoniae for each mAb. All error bars indicate s.d.
at each data point
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activity of KPN70 against O1 suggests that LPS neutralization in
the absence of opsonophagocytic killing may preferentially pro-
vide limited beneﬁt in the bacteremia model vs. the pneumonia
model. KPE33 also protected against dissemination to distal
organs from necrotic tissue at the burn site in a murine model of
thermal injury (Fig. 5c), suggesting the utility of anti-O-antigen
mAbs to protect in multiple infection models. Further in vivo
testing using additional strains (including Kp8045, a highly
virulent, mucoid K1 strain39) in a pneumonia model (Supple-
mentary Fig. 5a), conﬁrmed the high level of serotype-speciﬁc
protection mediated by the KPE33 and KPN42 mAbs as well as
the inferior activity of the cross-reactive, LPS neutralizing mAb
KPN70. Interestingly, KPE33 and KPN42 showed in vivo activity
even though mAb in vitro activity was restricted to capsule-
deﬁcient strains (Fig. 4d, Supplementary Fig. 4). The data from
this panel of mAbs, in concert with recently published data
showing that an opsonophagocytic killing deﬁcient mutant
KPE33 loses activity in vivo40, supports opsonophagocytic killing
activity against speciﬁc epitopes as a major mechanism of in vivo
protection, at least in the pneumonia model. Conversely, a ben-
eﬁcial role for LPS neutralization may be more limited and
dependent on the type of infection.
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Fig. 5 Anti-O1 and anti-O2 mAbs are protective in vivo. a Therapeutic activity of the mAbs was tested in C57BL/6 mice infected intranasally with a K.
pneumoniae O1 (Kp1131115, 6 × 107 CFU) or O2 (Kp961842, 2 × 108 CFU) strain. KPE33 (anti-O1), KPN42 (anti-O2) and KPN70 (anti-O1/O2) mAbs were
administered intravascular 1 h post infection at the doses indicated. An isotype-matched mAb (c-IgG) was used as a negative control. b Prophylactic
activity of the mAbs was tested in C57BL/6 mice infected intraperitoneal with the O1 strain Kp1131115 (3 × 106 CFU) or the O2 strain Kp961842 (1 × 107
CFU). mAbs were administered IP 24 h prior to infection at the doses indicated; survival was monitored for 5 days post infection. c CF1 mice received a
dorsal burn followed by K. pneumoniae O1 (Kp1131115, 5 × 106) bacterial inoculation subcutaneously at the burn site. KPE33 (45 or 15 mpk) or isotype-
matched control mAb (c-IgG, 45 mpk) were administered IP 24 h post infection, and organs were harvested 48 h post infection to determine bacterial CFU.
All graphs are representative of at least three separate experiments. Mantel-Cox analysis was done to assess signiﬁcant survival beneﬁt compared to the
control mAb. For thermal injury CFU comparison, Kruskal Wallace one way Anova analysis was done to compare differences in CFU between KPE33
treated vs. control IgG treated groups, ****p< 0.0001, ***p< 0.001, **p< 0.01
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Anti-O-antigen mAbs protection is synergistic with antibiotics.
Clinical application of anti-KP antibodies would likely be in
combination with current standard of care antibiotic treatments,
including a carbapenem such as meropenem. We therefore
assessed the potential for the anti-O1 and O2 mAbs to comple-
ment antibiotic therapy using sub-therapeutic doses of antibiotics
to simulate insufﬁcient drug exposure against drug-resistant
strains, as described previously10, 11, 41. These experiments were
performed using identical conditions to the pneumonia model
described in Fig. 5a with the additional administration of mer-
openem. A sub-therapeutic dose of mAb KPE33 administered in
combination with a sub-protective meropenem dose provided
signiﬁcant protection in the murine pneumonia model against a
intermediately meropenem-resistant O1 strain (MIC = 2 µg ml−1).
Statistical analysis conﬁrmed synergistic adjunctive activity
compared to either drug administered alone (Fig. 6a). The efﬁ-
cacy of the mAb was maintained even when administered 24 h
post infection (Fig. 6b). Similarly, a sub-therapeutic dose of mAb
KPN42 in combination with a dose approximating a human-
equivalent level of meropenem, also provided signiﬁcant protec-
tion in this model against a highly meropenem-resistant O2 CRE
ST258 strain (MIC = 32 µg ml−1, eight times more than the
human breakpoint) (Fig. 6a). These data clearly illustrate that
mAbs targeting O-antigen could not only provide protection
when dosed sufﬁciently in monotherapy, but could also provide
complementary synergistic activity in adjunctive therapy with
antibiotics. In conclusion, these results indicate that anti-O-
antigen antibodies can provide additional and complementary
beneﬁts to antibiotic therapy even against highly carbapenem-
resistant KP strains and further substantiate the concept of
antibody help in antibiotic therapy10, 11, 41. Without this
additional antibody-mediated help, O2 strains may preferentially
persist under antibiotic pressure.
Discussion
K. pneumoniae is a common enteric bacterial species in human
gut ﬂora, therefore basal levels of antibody to immunodominant
antigens are to be expected and were indeed evident in our survey
of tonsillar and circulating memory B cells. In our efforts to
identify protective mAbs against K. pneumoniae, only a small
fraction of antibodies recognizing whole bacteria possessed potent
opsonophagocytic killing activity, the majority of which recog-
nized LPS O-antigen. It is reasonable to consider that humoral
immunity to O-antigen may offer some level of protection against
the establishment of systemic infections in healthy individuals,
and these antigens are currently under clinical investigation as a
vaccine target against other pathogens such as nontyphoidal
Salmonella, Vibrio cholera and Shigella sonnei42–46, though in
each case the antibody activity was veriﬁed against unencapsu-
lated strains only. Our study determined for the ﬁrst time that the
O2 serotype comprises a signiﬁcantly larger fraction of ESBL
(35%) and CRE (50%) strains in comparison to fully susceptible
(17%) KP strains suggesting a selective advantage for MDR
strains of the O2 serotype despite their susceptibility to serum
killing. Much attention has been focused on the particularly
successful MDR carbapenem-resistant ST258 sequence type of K.
pneumoniae, which we serotyped as almost exclusively O2.
However, as ST258 only accounts for half of CRE strains and a
much smaller fraction of the earlier emerging ESBL strains,
simple clonal outbreaks cannot completely account for the
increased prevalence of the O2 serotype.
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Fig. 6 Antibody synergy with antibiotic. aMice were infected intranasally as in Fig. 5 with the K. pneumoniae O1 (Kp1131115, 6 × 107 CFU) or O2 (Kp961842,
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beneﬁt compared to the control mAb+MEM b, ****p< 0.0001, ***p< 0.001, **p< 0.01
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A possible explanation for the unexpected prevalence of the
serum-susceptible O2 serotype is the lower immunogenicity of
the O-antigen and the consequent failure to induce antibodies
that synergize with antibiotics. Thus, the combination of drug
resistance and lack of immunogenicity observed in this study may
contribute to the success of O2 strains (including the
ST258 subset) particularly in the context of broad spectrum
antibiotic pressure. It is notable that strains without a detectable
O-antigen (non-serotypeable) were also more prevalent in CRE
isolates. This observation further supports the concept that strains
with less immunogenic O antigen or lacking O antigen expression
may be selected under antibiotic pressure. However, immuno-
genic O1 strains are also prevalent among ESBL isolates and
slightly increased in prevalence compared to their representation
in susceptible isolates. In this instance, other O1-speciﬁc
mechanisms of immune evasion may play a role such as their
resistance to human serum killing (Fig. 1b) and/or the increased
presence of virulence genes in O1 isolates vs. other serotypes16.
Human serum sensitivity may play a role in bacterial clearance in
patients, but would not necessarily be expected to translate to
mouse models as species-speciﬁc differences in serum sensitivity
have been clearly demonstrated for several pathogens, including
K. pneumoniae26–30.
A diminishing pipeline for new antibiotics and the now
recognized negative impact of broad-spectrum antibiotics on the
beneﬁcial microbiome highlight the necessity of developing new
antibacterial strategies47. The diversity of capsular poly-
saccharides of K. pneumoniae has been suggested by many to be
an immunodominant feature that obscures the accessibility of
antibodies to other surface targets. Here, we demonstrate that it is
possible to identify highly protective mAbs to the less diverse O-
antigen. Despite the relative rarity of O2 antigen-speciﬁc B cells, it
was possible to identify a mAb (KPN42) with high protective
activity. Potent mAbs targeting the O1 antigen were also identi-
ﬁed. Interestingly, these mAbs had no opsonophagocytic killing
activity against WT strains in vitro. However, in vitro activity
against capsule knock-out strains was found to be predictive of
activity against WT encapsulated strains in vivo, suggesting
capsule may be expressed at lower levels or less consistently
in vivo. Consistent with previous studies with other bacterial
pathogens10, 11, the anti-KP mAbs isolated in this study afforded
synergistic adjunctive protection to drug-resistant strains,
including a representative strain of the problematic ST258 CRE
clone. These data further support an under-appreciated role for
humoral immunity in antibiotic therapy against KP and indeed
the background impact of immunity on bacterial drug resistance
observed with vaccines9. Furthermore, these studies provide some
encouragement that mAb-based strategies may offer future
solutions for combatting antibiotic refractory bacteria.
Methods
K. pneumoniae strains. All K. pneumoniae isolates were purchased from America
Type Culture Collection (ATCC), Euroﬁn or IHMA (a complete list of strains can
be found in Supplementary Table 2), and cultures were maintained in 2xYT media
at 37 °C supplemented with antibiotics when appropriate. For capsule mutant
strain generation, approximately one kilobase of DNA ﬂanking either side of the
cpsB/manC gene was PCR ampliﬁed and cloned into the pir-dependent plasmid
pDMS19748. This plasmid was then electroporated into Klebsiella strains and
plasmid integrants selected on LB agar containing 10 μg ml−1 tetracycline or gen-
tamycin. After propagation of recombinants in the absence of selection, clones that
resolved the integrated plasmid were selected by growth on LB agar containing 10%
sucrose. Deletion of manC was conﬁrmed by PCR on lysed colonies with primers
speciﬁc to the manC gene (AAACAGTTCCTCCGTCTGTTC, GGAA-
TAAAGGTGGACTGGTTCT) using the following cycling conditions: 94° for 2
min, 30 cycles of 94° for 30 s, 58° for 30 s, then 72° for 1 min.
Clinical isolates. For serotyping, clinical isolates were obtained from International
Health Management Associates (Schaumburg, IL, USA). The isolates were selected
based on MIC proﬁles (to ensure relatively equal numbers of susceptible, ESBL and
CRE strains), then chosen from 6 continents, 38 different countries and at least 162
different hospitals in an attempt to generate a global snapshot of current K.
pneumoniae infections as opposed to a sampling of any single outbreak. All isolates
were collected between 2012 and 2014 from various sites of infection (a breakdown
of infection site can be found in Supplementary Table 1).
Isolation and production of LPS serotyping antibodies. Peripheral blood
mononuclear cells (PBMC) and sera were separated from buffy coats of healthy
blood donors or convalescent patients after K. pneumoniae infection as previously
described49. Alternatively, lymphocytes were obtained from tonsils after tissue
homogenization in the presence of DNase I and collagenase. The donors provided
written informed consent for the use of these samples, following approval by the
Cantonal Ethical Committee of Canton Ticino, Switzerland (for healthy donors) and
the Ethical Committee of the Policlinico San Matteo, IRCCS, in Pavia (Italy) (for
convalescent ICU donors). Memory B cells were isolated from cryopreserved PMBC
or from lymphocytes isolated from tonsils using PE-Cy7-labeled CD19 microbeads
(BD Biosciences, clone SJ25C1), followed by isolation with anti PE-beads (Miltenyi
Biotec) and by depletion of cells stained with anti-IgM (Jackson ImmunoResearch),
anti-IgD (BD Biosciences), and anti-IgA (Novex) antibodies by cell sorting on a
FACSAria (BD Biosciences). Memory B cells were immortalized with EBV as
described previously36, 50 Brieﬂy, sorted memory B cells were infected with EBV and
seeded into 384 well plates in the presence of CpG TRL9 agonist and allogenic
irradiated PBMCs. Immortalized memory B cells were then screened for antibody
binding to puriﬁed LPS by ELISA. Total mRNA from positive B cell cultures was
reverse transcribed in 50 µl nuclease-free water (Ambion) using 15 µM speciﬁc pri-
mer (IgG:5′-TCTTGTCCACCTTGGTGTTGCT; Igκ: 5′ACACTCTCCCCTGTT-
GAAGCTCTT; Igλ: 5′-ACTGTCTTCTCCACGGTGCT), 1.8 µl of 25 mM dNTP
mix (GE Healthcare), 5 µl of 0.1M DTT, 0.5% v/v Igepal CA-630 (Sigma), 60 U
RNAse OUT (Invitrogen), and 100 U Superscript III reverse transcriptase (Invitro-
gen). Reverse transcription (RT) was performed at 42 °C 10min, 55 °C 60min, and
94 °C 5min. IgH, Igκ, and Igλ genes were ampliﬁed by PCR using HotStar Taq DNA
polymerase (Qiagen) and cloned into human Igγ1, Igκ, and Igλ expression vectors, as
described51. Recombinant mAbs were produced by transient transfection of EXPI293
cells (Invitrogen) and puriﬁed by Protein A chromatography (GE Healthcare) and
desalted against PBS. Alternatively, mouse immune sera were generated by puriﬁed
LPS or bacterial immunization. The speciﬁcity of the resulting mAbs and polysera
was conﬁrmed by loading 1 μg of puriﬁed LPS from serotype reference strains onto
an sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed
by transfer onto a nitrocellulose membrane, and probed using our isolated anti-O-
antigen mAbs or polyclonal mouse sera (Supplementary Fig. 1a).
Enzyme-linked immunosorbent assay. Spectraplate-384 with high protein
binding treatment (custom made from Perkin Elmer) or Nunc 96-well high
binding plates were coated overnight at 4 °C with 5 µg ml−1 LPS in phosphate-
buffered saline (PBS), pH 7.2, and plates were subsequently blocked with PBS
supplemented with 1% BSA (low endotoxin, Sigma-Aldrich). The coated plates
were incubated with serial dilutions of our isolated anti-O-antigen human
monoclonal antibodies for 1 h at room temperature. The plates were then washed
with PBS containing 0.1% Tween-20 (PBS-T), and alkaline phosphatase-afﬁniPure
F(ab’)2 Frag rabbit anti-human IgG, Fcg Frag Speciﬁc (Jackson ImmunoResearch,
10,000× dilution) or alkaline phosphatase-goat anti-human IgG (Southern Biotech)
were added and incubated for 1 h at room temperature. Plates were washed three
times with PBS-T, and P-NitroPhenyl Phosphate (pNPP, Sigma-Aldrich) substrates
were added and the absorbance of 405 nm was measured by a microplate reader
(Biotek or Molecular Devices). Data were plotted with GraphPad Prism software.
AMBRA of IgG and IgM antibodies from tonsillar B cells. Replicate cultures of
total tonsillar lymphocytes were seeded at 20,000 cells per well in 96 U-bottom
plates (Costar) and stimulated with 2.5 μg ml−1 R848 (3 M) and 1000 Uml−1
human recombinant IL-2 for 10 days at 37 °C 5% CO2. The cells culture super-
natants were collected for further analysis. Spectraplate-384 with high protein
binding treatment (Perkin Elmer) or Nunc 96-well high binding plates were coated
overnight at 4 °C with 5 µg ml−1 O1 or O2 LPS in phosphate-buffered saline (PBS).
Plates were blocked with PBS 1% BSA (low endotoxin, Sigma-Aldrich) and then
incubated with AMBRA supernatant for 1 h at room temperature. After washings
with PBS 0.1% Tween the binding of IgG or IgM Abs was detected with goat
Alkaline Phosphatase-anti human IgG (Southern Biotech) or Alkaline
Phosphatase-goat anti human IgM (Southern Biotech), respectively. pNPP (Sigma-
Aldrich) substrate was added and absorbance measured at 405 nm on a microplate
reader (Biotek).
Serotyping of K. pneumoniae clinical isolates. The serotypes of the KP clinical
isolates were determined by western blot analysis with serotype-speciﬁc mono-
clonal antibodies or mouse polysera. Brieﬂy, puriﬁed LPS or bacterial lysates were
subjected to SDS-PAGE. Separated proteins and LPS were transferred from gels to
nitrocellulose membranes with an iBlot apparatus (Life Technology). Membranes
were then blocked with Casein or Odyssey (Li-cor) blocking buffer before being
probed with anti-O1, O1/O2, O3, O4, or O5 LPS monoclonal antibodies or anti-O7
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and anti-O12 mouse polysera. After repeated washes with PBS-T, blots were
incubated with IRDye680 or 800 ﬂuorescent secondary antibodies (Li-cor) and
visualized with an Odyssey Image Station (Li-cor). In some circumstances, bacterial
lysates were treated with 0.4 mg ml−1 Proteinase K (ThermoScientiﬁc) to remove
protein components before the western blot analysis. CRE isolates were deﬁned as
resistant to carbapenams (doripenam, imipenam and/or meropenam MIC > = 4 μg
ml−1), ESBL isolates deﬁned as resistant to cephalosporins (ceftazidime MIC> =
16 μg ml−1) but sensitive to carpapenams (MIC < 4 μg ml−1) and susceptible iso-
lates deﬁned by ceftazidime MIC < 16 μg ml−1 and carbapenam MIC< 4 μg ml−1.
Octet binding assay with anti-LPS mAbs. Anti-LPS mAbs diluted to 0.2 µg ml−1
in PBS were immobilized for 10 min at 37 °C on the surface of a protein A coated
sensor-chip of an Octet RED96 system (FortéBio). Coated-Biosensors were incu-
bated for 10 min with a solution containing 2 µg ml−1 O1 or O2 LPS (puriﬁed from
Kp43816ΔcpsB or Kp8570ΔcpsB, respectively) in Kinetics buffer (ForteBio, dilute
10× to 1× with PBS). A dissociation step was then performed incubating the
Biosensor for 20 min in Kinetics buffer. Changes in the number of molecules
bound to the biosensor caused a shift in the interference pattern that was recorded
in real time and off-rate analyses were performed to determine mAbs KD (M).
Blockade of binding assay. Human anti-LPS mAbs were biotinylated using the
EZ-Link NHS-PEO solid phase biotinylation kit (Pierce). Labeled mAbs were tested
for binding to LPS by ELISA and the optimal concentration of each mAb to achieve
70% maximal binding was determined. Unlabeled mAbs were serially diluted and
added to ELISA 96-well plates (Corning) coated overnight at 4 °C with 5 µg ml−1
LPS in PBS. After 1 h, biotinylated anti-LPS mAbs were added at the concentration
achieving 70% maximal binding and the mixture was incubated at room tem-
perature for 1 h. Plates were washed and antibody binding was revealed using
Alkaline Phosphatase-streptavidin (Jackson Immunoresearch). After washing,
pNPP substrate (Sigma-Aldrich) was added and plates were read at 405 nm. The
percentage of inhibition was calculated as a percent decrease of signal vs. the
maximum signal achieved with the labeled mAb.
MLST analysis. Multi-locus sequence type (MLST) analysis was performed using
the method and primers as described elsewhere52. Brieﬂy, a bacterial colony was
resuspended in 40 μl DNase free water and used as template for PCR reactions
using primers speciﬁc to each of the seven MLST genes with the inclusion of a
universal 3′ sequence tag on each primer (rpoB forward GTTTTCCCAGTCAC-
GACGTTGTAGGCGAAATGGCWGAGAACCA, reverse TTGTGAGCGGA-
TAACAATTTCGAGTCTTCGAAGTTGTAACC; gapA forward
GTTTTCCCAGTCACGACGTTGTATGAAATATGACTCCACTCACGG,
reverse TTGTGAGCGGATAACAATTTCCTTCA-
GAAGCGGCTTTGATGGCTT; mdh forward GTTTTCCCAGTCAC-
GACGTTGTA CCCAACTCGCTTCAGGTTCAG, reverse
TTGTGAGCGGATAACAATTTCCCGTTTTTCCCCAGCAGCAG; pgi forward
GTTTTCCCAGTCACGACGTTGTAGAGAAAAACCTGCCTGTACTGCTGGC,
reverse TTGTGAGCGGATAACAATTTCCGCGCCACGCTTTA-
TAGCGGTTAAT; phoE forward GTTTTCCCAGTCACGACGTTGTAACC-
TACCGCAACACCGACTTCTTCGG, reverse
TTGTGAGCGGATAACAATTTCTGATCAGAACTGGTAGGTGAT; infB for-
ward GTTTTCCCAGTCACGACGTTGTACTCGCTGCTGGACTATATTCG,
reverse TTGTGAGCGGATAACAATTTC CGCTTTCAGCTCAAGAACTTC;
tonB forward GTTTTCCCAGTCACGACGTTGTACTTTATACCTCGGTA-
CATCAGGTT, reverse TTGTGAGCGGATAA-
CAATTTCATTCGCCGGCTGRGCRGAGAG). After exonuclease clean up using
Exo-SapIT (Affymetrix), the resulting template was used for a BigDye Terminator
(Affymetrix) PCR reaction according to the manufacturer’s protocol using uni-
versal primers for all 7 genes (forward GTTTTCCCAGTCACGACGTTGTA,
reverse TTGTGAGCGGATAACAATTTC) followed by analysis on the ABI 3730
(Applied Biosystems). SeqScape software (ABI) was used to match sequence data to
the public database (http://bigsdb.pasteur.fr/klebsiella/klebsiella.html) and to
determine the ST of each strain. In some cases, assembled whole genome sequences
were used to determine ST type.
Opsonophagocytic killing assays. Opsonophagocytic killing activity of anti-O
antigen mAbs was tested against O1 and O2 strains. Brieﬂy, log phase cultures of
luminescent KP strains 8570ΔcpsBlux (O2) and 43816ΔcpsBlux (O1) were diluted
to ~2 × 106 cells ml−1. Bacteria, 5 × 105 dimethylformamide (DMF) differentiated
HL-60 cells, 1:10 diluted cleared baby rabbit serum (Cedarlane), and a series
dilution of antibodies (2 ng–2500 ng m1) were mixed in 96-well plates and incu-
bated at 37 °C for 2 h with shaking (250 rpm). The relative light units (RLUs) were
then measured using an Envision Multilabel plate reader (Perkin Elmer). The
percent killing was determined by comparing RLU derived from assays with no
antibodies to RLU derived from assays with anti-KP or negative control mAbs.
Confocal imaging. K. pneumoniae strains were inactivated with formaldehyde,
washed and re-suspended in PBS to achieve an OD600 of 3. In each experimental
condition, 50 µl of bacterial suspension were centrifuged and re-suspended in 5%
FBS in PBS. The tested mAbs were added to the bacterial suspension at a ﬁnal
concentration of 10 µg ml−1 and incubated for 2.5 h at 4 °C. After two wash steps,
ﬂuorescent anti-human IgG secondary antibody (Jackson Immunoresearch) and
DAPI were added to the pellet to a ﬁnal concentration of 15 µg ml−1 and 4 µg ml−1,
respectively, and incubated for 40 min at 4 °C. Bacteria were washed twice with
PBS, resuspended in a Mowiol-based mounting medium and mounted on
microscopy slides. Slides were air-dried O/N in the dark and images were taken
using the TCS SP5 microscopy system from Leica using a ×100 objective and
confocal settings.
LPS neutralization assays. A murine RAW264.7 macrophage cell line was
engineered to carry a ﬁreﬂy luciferase reporter gene under the control of an NF-κB-
responsive promoter (RAW264.7-lux). Serially diluted antibody stocks were mixed
with puriﬁed KP LPS (2 ng ml−1 ﬁnal concentration) and incubated at 4 °C for 1 h.
Antibody/LPS mixtures were then added to assay plates containing pre-seeded
RAW264.7-lux cells (5000 cells per well). Plates were incubated for 2.5 h at 37 °C
with 5% CO2 then Steady Glo solution (Promega) was added to each well and
incubated for another 20 min protected from light. The RLUs were measured using
an Envision Multilabel plate reader (Perkin Elmer). The percentage of inhibition
was determined by comparing RLU derived from assays with no antibodies to RLU
derived from assays with anti-KP or negative control mAbs.
Bacterial infection models. C57BL/6 mice were received from Jackson labora-
tories and maintained in a special pathogen free facility. All animal experiments
were conducted in accordance with IACUC protocol and guidance. K. pneumoniae
strains were grown on agar plates overnight and diluted in saline at proper con-
centration just prior to infection. The inoculum titer was determined by plating a
serial dilution of bacteria onto agar plates. Mice were inoculated with 5 × 103 to 2 ×
108 CFU of KP clinical isolates either intranasally (pneumonia model) or intra-
peritoneally (bacteremia model). Anti-LPS monoclonal antibody and human IgG1
control antibody were administered IV 1 h post-bacterial challenge (therapeutic
dosing) or IP 24 h prior to infection (prophylactic dosing). Mouse survival was
monitored daily. For the thermal injury model, CF1 mice (Charles River Labora-
tories) received a dorsal burn under anesthetic for 5 s followed by administration of
5 × 106 bacteria subcutaneously at the burn site. MAb was administered IP 24 h
post infection, organs were harvested at 48 h post infection and bacterial CFU was
determined by serial dilution of organ homogenate. For antibody and antibiotic
combination studies, both were given 1 h post infection (mAb delivered IV, mer-
openem delivered subcutaneously at 7.5 mg kg−1 in O1 model or 50 mg kg−1 in O2
model). For extended timecourse experiments, meropenem was delivered 4 h post
infection and mAb 24 h post infection. Survival data was plotted in Prism and
statistical analysis was determined using the Log-rank Mantel-Cox test. To
determine synergy in the antibody/antibiotic combination experiments, the Bliss
independence method for drug combination synergy test was used as described
elsewhere53. Brieﬂy, if the rate of survival at the end of study for drug A alone is ra
and the survival rate for drug B alone is rb, then the expected survival rate for drug
A and drug B combination is rBliss = ra + rb − rarb assuming that the two drugs are
bliss independent. The difference between the observed survival rate rab and the
expected rate is deﬁned as the synergy index.
Ethics statement. The donors provided written informed consent for the use of
blood samples, following approval by the Cantonal Ethical Committee of Canton
Ticino, (Switzerland), for healthy donors and the Ethical Committee of the Poli-
clinico San Matteo, IRCCS, in Pavia (Italy) for convalescent and intensive care
donors. All animal studies were performed under the guidance and protocol
approval of the MedImmune Institutional Animal Care and Use Committee.
Additional oversight was also provided by Ofﬁce of Research Protections (ORP),
US Army Medical Research and Material Command (USAMRMC), Animal Care
and Use Review Ofﬁce (ACURO).
Data availability. The authors declare that all relevant data supporting the ﬁndings
of the study are available in this article and its Supplementary Information ﬁles, or
from the corresponding author upon request.
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